Enerceptan (etanercept biosimilar) / AMEGA Biotech - LARVOL DELTA

Biosimilars for Chronic Inflammation Management - Episode 2: Difference Between Biosimilars and Reference Product (Rheumatology Network) - "Joel M. Gelfand, MD, MSCE, FAAD: They are just that. The reference product is usually the originator biologic, the one that did large-scale pivotal trials, often placebo-controlled or active comparator studies, competitor studies, or some type of standard of care. We've been using a lot of these molecules for decades. For example, etanercept and infliximab were approved in the late 1990s. Then the biosimilar product is a manufactured biologic process that, as you mentioned, doesn't differ chemically or structurally in any important ways from the originator product, and then clinically has demonstrated very similar safety and efficacy."

Video